Treatment with a polymyxin B filter to capture endotoxin in sepsis patients: is there a signal for therapeutic efficacy?

Intensive Care Medicine

Volumn 45, Issue 2, 2019, Pages 282-283

  Pickkers, Peter ^a   Russell, James A ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; POLYMYXIN B; ANTIINFECTIVE AGENT;

APACHE; DISEASE SEVERITY; EDITORIAL; GRAM NEGATIVE SEPSIS; HUMAN; MEAN ARTERIAL PRESSURE; META ANALYSIS (TOPIC); MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; MICROBIOLOGY; PATHOPHYSIOLOGY; SEPSIS;

ANTI-BACTERIAL AGENTS; APACHE; ENDOTOXINS; HUMANS; POLYMYXIN B; SEPSIS;

EID: 85058039175     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-018-5481-5     Document Type: Editorial

References (8)

1. Opal SM et al (1999) Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 180(5):1584–1589
2. Zhou F et al (2013) Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med 41(9):2209–2220
3. Cruz DN et al (2009) Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301(23):2445–2452
4. Vincent JL (2009) Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA 302(18):1968 (author reply 1969–70)
5. Payen DM et al (2015) Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 41(6):975–984
6. Dellinger R et al (2018) Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the euphrates randomized clinical trial. JAMA 320(14):1455–1463
7. Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M (2018) Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. ICM. 10.1007/s00134-018-5463-7
8. Opal SM et al (2013) Effect of eritoran, an antagonist of md2-tlr4, on mortality in patients with severe sepsis: the access randomized trial. JAMA 309(11):1154–1162